Key statistics
As of last trade Entrada Therapeutics Inc (TRDA:NMQ) traded at 11.18, -19.10% below its 52-week high of 13.82, set on Feb 24, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 10.93 |
|---|---|
| High | 11.36 |
| Low | 10.74 |
| Bid | 11.10 |
| Offer | 11.17 |
| Previous close | 10.88 |
| Average volume | 172.52k |
|---|---|
| Shares outstanding | 38.22m |
| Free float | 32.78m |
| P/E (TTM) | -- |
| Market cap | 415.83m USD |
| EPS (TTM) | -2.50 USD |
Data delayed at least 15 minutes, as of Feb 17 2026 16:43 GMT.
More ▼
Announcements
- Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
- Entrada Therapeutics to Present at Upcoming Investor Conferences
- Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
- Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Entrada Therapeutics Reports Third Quarter 2025 Financial Results
- Entrada Therapeutics to Present at Upcoming Investor Conferences
- Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program
- Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Entrada Therapeutics Reports Second Quarter 2025 Financial Results
More ▼
